ProCE Banner Activity

CE / CME

The Latest in Stroke Risk Reduction Strategies: Are Your Patients Protected?

Video

Listen to expert faculty discuss the role of GLP-1RAs in reducing stroke risk for patients with type 2 diabetes in this on-demand webcast with accompanying slides

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: January 03, 2025

Expiration: January 02, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Target Audience

This activity is intended for neurology, primary care, and endocrinology providers (physicians, nurse practitioners, and physician associates) and other healthcare professionals who manage patients with diabetes with history of or at risk for stroke.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Diabetes.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Identify the known and proposed mechanisms by which GLP-1 RAs contribute to stroke risk reduction

  • Analyze the most recent evidence for GLP-1 RAs in stroke risk reduction in patients with T2D

  • Develop individualized treatment plans for patients with T2D to reduce the risk of stroke

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Richard E. Pratley, MD

AdventHealth Samuel E. Crockett Chair in Diabetes Research
Medical Director, Advent Health Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins School of Medicine
Orlando, Florida

Richard E. Pratley, MD: consultant/advisor/speaker: AbbVie, Altanine, AstraZeneca, Bayer AG, Bayer HealthCare, Boehringer Ingelheim, Corcept, Endogenex, Gasherbrum Bio, Genprex, Getz Pharma, Intas, Lilly, Lilly USA, Novo Nordisk, Pfizer, Rivus, Scholar Rock, Sun Pharmaceutical; researcher: Biomeda Fusion, Carmot Therapeutics, Dompe, Endogenex, Fractyl, Lilly, Novo Nordisk, Sanofi, Scholar Rock; individual publicly traded stocks/stock options: Altanine.

Alejandro A. Rabinstein, MD, FAHA

Professor of Neurology
Chair, Hospital Neurology and Neurocritical Care Division
Mayo Clinic
Rochester, Minnesota

Alejandro A. Rabinstein, MD, FAHA: advisor: Ceribell, Chiesi, Shionogi; other financial or material support: Boston Scientific.

Jay H. Shubrook, DO, FACOFP, FAAFP

Professor and Diabetologist
Department of Clinical Sciences and Community Health
Touro University California College of Osteopathic Medicine
Vallejo, California

Jay H. Shubrook, DO, FACOFP, FAAFP: consultant/advisor/speaker: Abbott, Bayer, Lilly, Madrigal, Novo Nordisk, Sanofi.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose except Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES as noted below:​

Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES: consultant/advisor/speaker: Abbott, Ascencia/Eversense, Bayer, Novo Nordisk, Xeris.​

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 03, 2025, through January 02, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

Physician Associate Continuing Medical Education

AAPA CME Accreditation - AAPA

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until January 02, 2026. PAs should only claim credit commensurate with the extent of their participation.

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.